LUGPA Meeting Will Offer Insights Into Urology Practice ManagementOctober 27th 2014
From a limited first meeting in the late 1990s that included the leaders of a dozen large group practices, LUGPA has grown so much that its annual meeting this November will include up to 550 physicians and 200 administrators, filling the organization's usual Chicago venue to capacity and necessitating a move to a larger space next year.
ICD-10 and Urologic Oncology: A Disappointing CombinationOctober 24th 2014
The 12-month countdown to the adoption of ICD-10 has begun. ICD-10 represents the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (usually referred to as "ICD"), now overseen by the World Health Organization (WHO).
How Test Reimbursement Decisions Are Made: A Leader of Medicare's MolDX Program Discusses Evaluation ProcessOctober 21st 2014
Despite the promise associated with biomarker-based tools as a means of helping to guide cancer diagnosis and treatment, there is a potential stumbling block: insurance reimbursement.
Commercial Tests Offer Guidance in Bladder, Renal, Testicular CancersOctober 7th 2014
While biomarker-based tools designed to guide the diagnosis and treatment of prostate cancer are emerging at an extraordinarily rapid rate, they are not exploding in the same practice-changing way in all genitourinary cancers.
Vogelzang Disputes 'Weak' Guideline Rating for Sipuleucel-TOctober 3rd 2014
In a recent guideline for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC), the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO) shared their thoughts on the implementation of six drugs approved since their previous recommendations were issued in 2007, as well as on older drugs.